GMP IPO
📋 Filings Intelligence
About Contact
LIVE - Auto-updated every 10 mins · Equity segment
Company Filings, Explained Simply

AI-powered plain-English analysis of every important corporate announcement - financial results, order wins, dividends, mergers and more. Updated live.

-
Filed today
-
Companies tracked
NSE & BSE
Listed on
Sign in free to search by company
Filing Type
Market Cap
Sector
All Sectors

Latest Filings -

📋 Filing Types Available on ForgeUp Filings Sourced from BSE corporate announcements (equity segment). Companies covered are BSE-listed and most are also listed on NSE. We show only material filings.
Financial Results Orders Dividend Buyback Merger / Acquisition Board Meeting Outcome Fundraise (QIP / Rights / FPO) Regulatory / Court Order Credit Rating Change Promoter Pledge Update Management Change Joint Venture / MOU Delisting Bonus Shares Stock Split
Data sourced from BSE India corporate announcements. More categories will be added over time.
Shilpa Medicare Ltd

Shilpa Biologicals' Bank Loan Rated IND A+ by India Ratings

RATING ▲ Positive Development LOW RISK
📅 Filed on BSE: 16 Jul 2026, 12:17 PM IST  ·  BSE ID: fe51383b-1660-42e2-a4b0-e3fb3d9e2c57
View Original BSE Filing (PDF)
💡
In Simple Terms
A credit agency has rated a key division of Shilpa Medicare, Shilpa Biologicals, as stable for its major loans.
🤖 AI Summary
  • Shilpa Biologicals' bank loan facilities rated IND A+ by India Ratings.
  • Subsidiary is Shilpa Biologicals Private Limited, a unit of Shilpa Medicare.
  • Assigned rating includes IND A1+ for short-term facilities.
  • Total size of the rated bank loan facilities is INR1,250 million.
  • Outlook for the rating is Stable.
🔢 Key Numbers - exact figures from BSE filing, not rounded
Size of Issue (million)
INR1,250
🏢 How This Affects the Company
📈
Business Impact
A strong credit rating can enhance the subsidiary's ability to access future debt financing on favorable terms, supporting its business operations and growth plans.
💰
Financial Impact
Improved credit ratings generally lead to lower borrowing costs, positively impacting the subsidiary's finance expenses and potentially improving its net profit margins.
⚠️
Risk Impact
This rating provides an independent assessment of the subsidiary's creditworthiness, offering some assurance regarding its financial stability to stakeholders.
👥 What This Means For Shareholders
✅
Action Required
No action is required from shareholders regarding this rating announcement.
👤
Who Is Affected
All shareholders are indirectly affected as the credit rating impacts the financial health and borrowing capacity of a material subsidiary.
🔍
Management Signal
This indicates management's success in maintaining and improving the credit profile of its key subsidiaries.

For information only. Not investment advice. ForgeUp is not SEBI-registered.

👁 Watch List - track these upcoming events
Subsequent rating reviews by India Ratings or other agencies.
Performance updates for Shilpa Biologicals' operations and financials.
Shilpa Medicare's consolidated financial results for FY27.
LOW RISK Credit rating provides an independent assessment of financial stability.
💡 Investor Takeaway
Shilpa Biologicals, a material subsidiary of Shilpa Medicare, has secured bank loan facilities of INR1,250 million rated IND A+/Stable/IND A1+ by India Ratings.
⚖️ Strengths & Concerns

✅ Positives

  • Shilpa Biologicals secured a substantial bank loan facility of INR1,250 million with a stable outlook.
  • The assignment of an IND A+ rating by India Ratings indicates financial soundness for the subsidiary.
📅 Company Track Record
This follows a recent rating upgrade for Shilpa Medicare's own bank loan facilities to IND AA- by India Ratings on July 7, 2026.

Based on publicly available historical data. For context only.

❓ Frequently Asked Questions
What is the credit rating assigned to Shilpa Biologicals Private Limited?
India Ratings assigned a rating of IND A+/Stable for long-term facilities and IND A1+ for short-term facilities to Shilpa Biologicals.
What is the size of the bank loan facilities rated for Shilpa Biologicals?
The total size of the rated bank loan facilities for Shilpa Biologicals is INR1,250 million.
Which agency assigned the credit rating to Shilpa Biologicals?
India Ratings and Research Pvt Ltd (Fitch Group) assigned the credit rating.
Is Shilpa Biologicals a material subsidiary of Shilpa Medicare Limited?
Yes, the filing clearly states that Shilpa Biologicals Private Limited is a material subsidiary of Shilpa Medicare Limited.

Questions based on this BSE filing only. For information purposes.

You've read one filing

There are 32,000 more, and one of them is about a company you own

Follow a company and we'll email you the moment it files again - explained, not just forwarded. Free.

  • Follow companies and get filings by email
  • Save any filing to read later
  • Two full AI analyses every month, free

No card needed. Sign in with Google in two taps.

⚠️ For Information Only - Not Investment Advice
ForgeUp Filings provides AI-generated summaries of public BSE exchange announcements (equity segment) for informational purposes only. Nothing here constitutes investment advice or a recommendation to buy, sell, or hold any security. ForgeUp is not a SEBI-registered investment advisor. All financial numbers are sourced directly from BSE filings and shown as-is. Past data is historical only. Please consult a qualified financial advisor before making investment decisions. Data sourced from BSE India public disclosures.
🔍
Sign in to use filters
Sign in free with Google to filter filings by category, market cap and sector - takes 5 seconds.